|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/17/23 Tengjun Biotechnology Corp. 10-K 12/31/22 71:4.5M EdgarAgents LLC/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 816K
2: EX-4.1 Description of Securities HTML 22K
3: EX-31.1 Certification -- §302 - SOA'02 HTML 24K
4: EX-31.2 Certification -- §302 - SOA'02 HTML 24K
5: EX-32.1 Certification -- §906 - SOA'02 HTML 20K
6: EX-32.2 Certification -- §906 - SOA'02 HTML 20K
12: R1 Document And Entity Information HTML 86K
13: R2 Consolidated Balance Sheets (Audited) HTML 128K
14: R3 Consolidated Balance Sheets (Audited) HTML 38K
(Parentheticals)
15: R4 Consolidated Statements of Operations and HTML 112K
Comprehensive Loss (Audited)
16: R5 Consolidated Statements of Operations and HTML 29K
Comprehensive Loss (Audited) (Parentheticals)
17: R6 Consolidated Statements of Changes in Deficit HTML 62K
(Audited)
18: R7 Consolidated Statements of Cash Flows (Audited) HTML 105K
19: R8 Organization and Nature of Business HTML 28K
20: R9 Liquidity HTML 23K
21: R10 Summary of Significant Accounting Policies HTML 82K
22: R11 Inventories, Net HTML 26K
23: R12 Property, Plant, and Equipment, net HTML 28K
24: R13 Prepaid Taxes HTML 23K
25: R14 Other Receivable HTML 26K
26: R15 Short-Term Loan HTML 23K
27: R16 Accrued Liabilities and Other Payables HTML 27K
28: R17 Income Tax HTML 42K
29: R18 Risks and Contingencies HTML 26K
30: R19 Related Party Transactions and Balances HTML 34K
31: R20 Equity HTML 31K
32: R21 Subsequent Events HTML 25K
33: R22 Accounting Policies, by Policy (Policies) HTML 141K
34: R23 Summary of Significant Accounting Policies HTML 55K
(Tables)
35: R24 Inventories, Net (Tables) HTML 27K
36: R25 Property, Plant, and Equipment, net (Tables) HTML 26K
37: R26 Other Receivable (Tables) HTML 25K
38: R27 Accrued Liabilities and Other Payables (Tables) HTML 27K
39: R28 Income Tax (Tables) HTML 39K
40: R29 Related Party Transactions and Balances (Tables) HTML 35K
41: R30 Organization and Nature of Business (Details) HTML 32K
42: R31 Liquidity (Details) HTML 29K
43: R32 Summary of Significant Accounting Policies HTML 57K
(Details)
44: R33 Summary of Significant Accounting Policies HTML 35K
(Details) - Schedule of straight-line method over
the estimated useful lives of the assets
45: R34 Summary of Significant Accounting Policies HTML 30K
(Details) - Schedule of one major supplier that
accounted for over 10% of its total purchases
46: R35 Summary of Significant Accounting Policies HTML 24K
(Details) - Schedule of exchange rates were used
to translate
47: R36 Summary of Significant Accounting Policies HTML 72K
(Details) - Schedule of operations by business
segment
48: R37 Summary of Significant Accounting Policies HTML 26K
(Details) - Schedule of segment assets
49: R38 Inventories, Net (Details) - Schedule of HTML 34K
inventories
50: R39 Property, Plant, and Equipment, net (Details) HTML 22K
51: R40 Property, Plant, and Equipment, net (Details) - HTML 37K
Schedule of property, plant, and equipment
52: R41 Prepaid Taxes (Details) HTML 22K
53: R42 Other Receivable (Details) HTML 22K
54: R43 Other Receivable (Details) - Schedule of other HTML 30K
receivable
55: R44 Short-Term Loan (Details) HTML 34K
56: R45 Accrued Liabilities and Other Payables (Details) - HTML 39K
Schedule of accrued liabilities and other payables
57: R46 Income Tax (Details) HTML 42K
58: R47 Income Tax (Details) - Schedule of income from HTML 27K
operations before income taxes
59: R48 Income Tax (Details) - Schedule of provision for HTML 41K
income tax expense (Benefit)
60: R49 Income Tax (Details) - Schedule of reconciliation HTML 35K
of income tax expense for operations
61: R50 Risks and Contingencies (Details) HTML 27K
62: R51 Related Party Transactions and Balances (Details) HTML 31K
- Schedule of related party with whom transaction
63: R52 Related Party Transactions and Balances (Details) HTML 30K
- Schedule of due from related party
64: R53 Related Party Transactions and Balances (Details) HTML 36K
- Schedule of due to related parties
65: R54 Equity (Details) HTML 65K
66: R55 Subsequent Events (Details) HTML 32K
69: XML IDEA XML File -- Filing Summary XML 129K
67: XML XBRL Instance -- f10k2022_tengjunbio_htm XML 698K
68: EXCEL IDEA Workbook of Financial Reports XLSX 110K
8: EX-101.CAL XBRL Calculations -- tjbh-20221231_cal XML 110K
9: EX-101.DEF XBRL Definitions -- tjbh-20221231_def XML 593K
10: EX-101.LAB XBRL Labels -- tjbh-20221231_lab XML 1.14M
11: EX-101.PRE XBRL Presentations -- tjbh-20221231_pre XML 601K
7: EX-101.SCH XBRL Schema -- tjbh-20221231 XSD 196K
70: JSON XBRL Instance as JSON Data -- MetaLinks 341± 491K
71: ZIP XBRL Zipped Folder -- 0001213900-23-030342-xbrl Zip 275K
Exhibit 32.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Form 10-K of Tengjun Biotechnology Corp., a company duly formed under the laws of Nevada (the “Company”), for the fiscal year ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Xianchang Ma, the Chief Executive Officer of the Company, hereby certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that:
| (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| Date: April 17, 2023 | /s/ Xianchang Ma |
|
Chief Executive Officer |
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 4/17/23 | |||
| For Period end: | 12/31/22 | NT 10-K | ||
| 12/31/21 | 10-K | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/15/24 SEC UPLOAD¶ 3/15/24 2:40K Tengjun Biotechnology Corp. 1/25/24 SEC UPLOAD¶ 3/15/24 2:41K Tengjun Biotechnology Corp. 7/21/23 SEC UPLOAD¶ 3/15/24 2:56K Tengjun Biotechnology Corp. |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 12/23/21 Tengjun Biotechnology Corp. 8-K:1,2,3,512/23/21 15:1.5M EdgarAgents LLC/FA 12/12/19 Tengjun Biotechnology Corp. 8-K:5,8,9 12/09/19 2:1.1M EdgarAgents LLC/FA 4/14/15 Tengjun Biotechnology Corp. 10-K 12/31/14 42:1.9M EdgarAgents LLC/FA 10/12/10 Tengjun Biotechnology Corp. S-1/A¶ 6:2.2M |